<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649385</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-15025-101</org_study_id>
    <nct_id>NCT04649385</nct_id>
  </id_info>
  <brief_title>BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of BGB-15025&#xD;
      alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD)&#xD;
      or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone&#xD;
      and in combination with tislelizumab in participants with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) of BGB-15025</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D of BGB-15025 monotherapy</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D of BGB-15025 in combination with tislelizumab</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) as assessed by the investigator</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR) as assessed by the investigator</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) as assessed by the investigator</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BGB-15025</measure>
    <time_frame>Predose up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed plasma concentration (Cmin) of BGB-15025</measure>
    <time_frame>Predose up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of BGB-15025</measure>
    <time_frame>Predose up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of (t1/2) of BGB-15025</measure>
    <time_frame>Predose up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of BGB-15025</measure>
    <time_frame>Predose up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F) of BGB-15025</measure>
    <time_frame>Predose up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of BGB-15025</measure>
    <time_frame>Predose up to 8 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1a: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Participants will receive once daily of BGB-15025 monotherapy in sequential cohorts of approximately 5 increasing doses for up to 6 months&#xD;
Part B: Participants will receive once daily of BGB-15025 in sequential cohorts plus 200mg tislelizumab on day 1 of each 21-day cycle (combination therapy ) for up to 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b dose expansion will begin based upon the recommended Phase 2 dose (RP2D) for BGB-15025 alone or in combination with tislelizumab as determined from Phase 1a</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-15025</intervention_name>
    <description>Administered orally once daily (QD)</description>
    <arm_group_label>Phase 1a: Dose Escalation</arm_group_label>
    <arm_group_label>Phase 1b: Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Administered 200 mg intravenous (IV) infusion</description>
    <arm_group_label>Phase 1a: Dose Escalation</arm_group_label>
    <arm_group_label>Phase 1b: Dose Expansion</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Phase 1a (dose escalation): Participants with histologically or cytologically&#xD;
             confirmed advanced, metastatic, and unresectable solid tumors who have previously&#xD;
             received standard systemic therapy or for whom treatment is not available, not&#xD;
             tolerated or refused, and who have not received prior therapy targeting HPK1&#xD;
&#xD;
          2. At least 1 measurable lesion as defined per RECIST 1.1. The target lesion(s) selected&#xD;
             have not been previously treated with local therapy or the target lesion(s) selected&#xD;
             that are within the field of prior local therapy have subsequently progressed as&#xD;
             defined by RECIST 1.1&#xD;
&#xD;
          3. Participants must be able to provide an archived formalin-fixed paraffin embedded&#xD;
             (FFPE) tumor tissue sample (block or approximately 15 to 17 freshly unstained FFPE&#xD;
             slides after the most recent line of therapy. If archival tissue is not available,&#xD;
             fresh tumor biopsy is mandatory&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1&#xD;
&#xD;
          5. Adequate organ function as indicated by the following laboratory values up to first&#xD;
             dose of study drug: Hemoglobin≥ 90 g/L, Absolute neutrophil count ≥ 1.5 x 109/L ,&#xD;
             Serum total bilirubin ≤ 1.5 x ULN (&lt; 3 x ULN for participants with Gilbert syndrome ),&#xD;
             AST and ALT≤ 2.5 x ULN (≤5 x ULNs for participants with hepatocellular carcinoma or&#xD;
             liver metastases )&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Active leptomeningeal disease or uncontrolled and untreated brain metastasis.&#xD;
             Participants with equivocal findings or with confirmed brain metastases are eligible&#xD;
             for enrollment provided that they are asymptomatic and radiologically stable without&#xD;
             the need for corticosteroid treatment for at least 4 weeks prior to the first dose of&#xD;
             study drug(s)&#xD;
&#xD;
          2. Active autoimmune diseases or history of autoimmune diseases that may relapse, with&#xD;
             the following exceptions:&#xD;
&#xD;
               1. Controlled Type 1 diabetes&#xD;
&#xD;
               2. Hypothyroidism (provided that it is managed with hormone-replacement therapy&#xD;
                  only)&#xD;
&#xD;
               3. Controlled celiac disease&#xD;
&#xD;
               4. Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, or&#xD;
                  alopecia)&#xD;
&#xD;
               5. Any other disease that is not expected to recur in the absence of external&#xD;
                  triggering factors&#xD;
&#xD;
          3. Any active malignancy ≤ 2 years before the first dose of study drug(s) except for the&#xD;
             specific cancer under investigation in this study and any locally recurring cancer&#xD;
             that has been treated with curative intent (eg, resected basal or squamous cell skin&#xD;
             cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast)&#xD;
&#xD;
          4. Any condition that required systemic treatment with either corticosteroids (&gt; 10 mg&#xD;
             daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days&#xD;
             before the first dose of study drug(s), with the following exceptions:&#xD;
&#xD;
               1. Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent)&#xD;
&#xD;
               2. Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with&#xD;
                  minimal systemic absorption&#xD;
&#xD;
               3. Short course (≤ 7 days) of corticosteroid prescribed prophylactically (eg, for&#xD;
                  contrast dye allergy) or for the treatment of a nonautoimmune condition (eg,&#xD;
                  delayed-type hypersensitivity reaction caused by contact allergen)&#xD;
&#xD;
          5. History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung&#xD;
             diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>+1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>One Gustave L Levy Place</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Yap</last_name>
      <phone>713-563-1784</phone>
    </contact>
    <contact_backup>
      <last_name>tyap@mdanderson.org</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Windsor</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gonzalo T Rico</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Lau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ADHB, Cancer &amp; Blood Research - Auckland Cancer Trials Centre</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

